2-(4-Methoxyphenyl)-4-oxo-4H-chromen-6-YL 2,2-dimethylpropanoate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 2-(4-Methoxyphenyl)-4-oxo-4H-chromen-6-YL 2,2-dimethylpropanoate
• 英文别名: [2-(4-methoxyphenyl)-4-oxochromen-6-yl] 2,2-dimethylpropanoate
• 化学式: C₂₁H₂₀O₅
• mdl: MFCD03847010
• 分子量: 352.4
• InChiKey: ZVALUBSBIVNXRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Liquid-crystalline medium
  申请人：MERCK PATENT GMBH

  公开号：US10208251B2

  公开（公告）日：2019-02-19

  The invention relates to a liquid-crystalline medium which comprises at least one compound of the formula I, in which R1, R1*, Z1, Z2 and L1-3 have the meanings defined herein, and to the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PALC, FFS, PS-FFS, PS-IPS or IPS effect.

  本发明涉及一种液晶介质，它包含至少一种式 I 的化合物、 其中 R1、R1*、Z1、Z2 和 L1-3 具有本文所定义的含义、 以及将其用于有源矩阵显示器，特别是基于 VA、PSA、PS-VA、PALC、FFS、PS-FFS、PS-IPS 或 IPS 效果的显示器。
• Liquid crystal medium
  申请人：MERCK PATENT GMBH

  公开号：US10557083B2

  公开（公告）日：2020-02-11

  The present invention relates to a liquid crystal (LC) medium comprising a terphenyl compound and at least two polymerisable compounds, to a process for its preparation, to its use for optical, electro-optical and electronic purposes, in particular in LC displays, especially in an LC display of the polymer sustained alignment (PSA) type, and to an LC display, especially a PSA display, comprising it.

  本发明涉及一种由三联苯化合物和至少两种可聚合化合物组成的液晶（LC）介质，涉及其制备工艺，涉及其在光学、电子光学和电子领域的用途，尤其是在液晶显示器中的用途，特别是在聚合物持续排列（PSA）型液晶显示器中的用途，还涉及由其组成的液晶显示器，特别是 PSA 显示器。
• LIQUID-CRYSTALLINE MEDIUM
  申请人：Merck Patent GmbH

  公开号：EP2628779B1

  公开（公告）日：2017-05-17
• ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE
  申请人：Magenta Therapeutics Inc.

  公开号：US20210220408A1

  公开（公告）日：2021-07-22

  The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies, such as cancer, by administration of these aryl hydrocarbon receptor antagonists. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells. The disclosure further relates to pharmaceutical compositions comprising the compounds and methods of treating or preventing a disease in which aryl hydrocarbon receptor plays a role.
• US9714381B2
  申请人：——

  公开号：US9714381B2

  公开（公告）日：2017-07-25